Mankind Pharma Limited v. The Registrar Of Trade Marks

When a pharmaceutical giant applies for a new trademark, you'd think the registration would be a formality. But when the Registrar of Trade Marks raises an objection citing similarity to another application, even industry leaders must fight for their brand identity. This is the story of how Mankind Pharma Limited turned a rejection into a victory by leaning on something far more powerful than a single trademark: a legacy of brand-building.

Mankind Pharma Limited, a well-known name in the Indian pharmaceutical industry, sought to register the trademark PETKIND under Class 5, which covers pharmaceutical and veterinary preparations. However, the Registrar of Trade Marks refused the application, pointing to an earlier existing application for the mark PETKIND PHARMA. The Registrar's concern was rooted in the potential confusion between the two marks due to their shared dominant element, 'PETKIND.' For Mankind Pharma, this refusal threatened to block the expansion of its brand portfolio in a market segment where it had already invested heavily in building recognition and trust.

Mankind Pharma challenged the Registrar's decision head-on. The Appellant argued that its extensive goodwill and long-standing presence in the pharmaceutical market entitled it to register the PETKIND mark. More importantly, Mankind Pharma pointed to its established 'KIND Family of Marks' — a portfolio of trademarks sharing the common 'KIND' suffix that had already earned consumer recognition and trust. The Appellant's position was that this family of marks gave it superior rights in the relevant market segment, distinguishing its application from the prior PETKIND PHARMA filing. On the other side, the Registrar maintained that the similarity between PETKIND and PETKIND PHARMA created a likelihood of confusion among consumers, justifying the refusal to register.

The Court ruled in favor of Mankind Pharma, allowing the appeal and setting aside the rejection order. The Court accepted the Appellant's argument that the establishment of a recognizable family of marks, combined with demonstrated goodwill and superior rights in the relevant pharmaceutical market segment, could overcome objections based on similarity to prior applications. By recognizing the strength of Mankind Pharma's 'KIND Family of Marks,' the Court effectively validated the company's brand-building strategy and cleared the path for the PETKIND registration.

For founders and IP professionals, this case delivers a clear lesson: building a recognizable family of marks is not just a branding exercise — it is a legal asset. When you consistently use a common element across your trademark portfolio and build genuine goodwill around it, you create a powerful shield against objections from prior similar applications. If you are a startup leader investing in brand identity, think beyond individual trademarks. Cultivate a cohesive family of marks, document your market presence and consumer recognition, and you may find that your brand legacy speaks louder than any conflicting application in the Registrar's database.